We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the last reported quarter, the company beat earnings expectations by 17.8%. The ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Valley Wealth Managers Inc. just upped their Amgen game by 8.1% this quarter, now holding a cool $27.15 million worth of ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

For Q2 2025, Aristotle Capital’s Global Equity Composite posted a total return of 9.58% gross of fees (9.45% net of fees), ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

Cetera Investment Advisers just upped their Amgen game, acquiring an additional 26,309 shares, now holding a hefty 226,219 ...

This was the stock's third consecutive day of losses.

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...